Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Characterization of the novel DNA gyrase inhibitor AZD0914: low resistance potential and lack of cross-resistance in Neisseria gonorrhoeae.

Antimicrobial agents and chemotherapy - 1 Mar 2015

Alm Richard A, Lahiri Sushmita D, Kutschke Amy, Otterson Linda G, McLaughlin Robert E, Whiteaker James D, Lewis Lisa A, Su Xiaohong, Huband Michael D, Gardner Humphrey, Mueller John P

Abstract excerpt

The unmet medical need for novel intervention strategies to treat Neisseria gonorrhoeae infections is significant and increasing, as rapidly emerging resistance in this pathogen is threatening to eliminate the currently available treatment options. AZD0914 is a novel bacterial gyrase inhibitor th...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Gyrase
Share to Drug Resistance, Bacterial

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Isoxazoles

Share to Morpholines

Share to Neisseria gonorrhoeae

Share to Oxazolidinones

Share to Spiro Compounds

Share to Topoisomerase II Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 25534723
DOI: 10.1128/AAC.04456-14
PMCID: PMC4325766

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-25534723-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Characterization of the novel DNA gyrase inhibitor AZD0914: low resistance potential and lack of cross-resistance in Neisseria gonorrhoeae.PMID 25534723Read ↗

Genetic Resistance Determinants, In Vitro Time-Kill Curve Analysis and Pharmacodynamic Functions for the Novel Topoisomerase II Inhibitor ETX0914 (AZD0914) in Neisseria gonorrhoeaeSemantic proximity Read ↗

High In Vitro Activity of the Novel Spiropyrimidinetrione AZD0914, a DNA Gyrase Inhibitor, against Multidrug-Resistant Neisseria gonorrhoeae Isolates Suggests a New Effective Option for Oral Treatment of GonorrheaSemantic proximity Read ↗

Using a public database of Neisseria gonorrhoeae genomes to detect mutations associated with zoliflodacin resistance.Semantic proximity Read ↗

Genomic Epidemiology and Molecular Resistance Mechanisms of Azithromycin-Resistant Neisseria gonorrhoeae in Canada from 1997 to 2014.Semantic proximity Read ↗

Inhibition of Neisseria gonorrhoeae Type II Topoisomerases by the Novel Spiropyrimidinetrione AZD0914.Semantic proximity Read ↗

Zoliflodacin and gepotidacin cross-resistance in <i>Neisseria gonorrhoeae</i>Semantic proximity Read ↗

In Vitro Activity of Delafloxacin against Clinical Neisseria gonorrhoeae Isolates and Selection of Gonococcal Delafloxacin ResistanceSemantic proximity Read ↗

Exploration of the <i>Neisseria</i> resistome reveals resistance mechanisms in commensals that may be acquired by <i>N. gonorrhoeae</i> through horizontal gene transferSemantic proximity Read ↗

Antibiotic resistance in Neisseria gonorrhoeae : origin, evolution, and lessons learned for the futureSemantic proximity Read ↗

Molecular epidemiology and mechanisms of resistance of azithromycin-resistant Neisseria gonorrhoeae isolated in France during 2013-14.Semantic proximity Read ↗

Local emergence and global evolution of Neisseria gonorrhoeae with high-level resistance to azithromycin.Semantic proximity Read ↗

Progression of antibiotic resistance in Neisseria meningitidisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.